Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho Showa-ku, Nagoya 466-8550, Japan.
Br J Surg. 2018 Jun;105(7):829-838. doi: 10.1002/bjs.10556. Epub 2017 May 10.
Bismuth type IV perihilar cholangiocarcinoma has traditionally been categorized as unresectable disease. The aim of this study was to review experience with a resection-based strategy in patients who have type IV perihilar cholangiocarcinoma.
Medical records of consecutive patients with a diagnosis of type IV perihilar cholangiocarcinoma between 2006 and 2015 were reviewed retrospectively. Primary outcomes assessed were surgical results and long-term survival.
Of the 332 patients with type IV tumour, 216 (65·1 per cent) underwent resection. Left hepatic trisectionectomy was the most common procedure (112 patients). Combined vascular resection was performed in 131 patients. Median duration of operation was 607 (range 356-1045) min, and blood loss was 1357 (209-10 349) ml. Complications of Clavien-Dindo grade III or more developed in 90 patients (41·7 per cent) and four (1·9 per cent) died from complications within 90 days. Survival rates were better for the 216 patients whose tumours were resected than for the 116 patients with unresected tumours (32·8 versus 1·5 per cent at 5 years; P < 0·001). Patients with pN0 M0 disease after resection had a favourable 5-year survival rate of 53 per cent. Percutaneous transhepatic biliary drainage, blood transfusion, lymph node metastasis and distant metastasis were identified as independent negative prognostic factors for survival.
Although resection for type IV tumour is technically demanding with high morbidity, it can be performed with low mortality and offers better survival probability in selected patients.
传统上,铋型 IV 肝门部胆管癌被归类为不可切除的疾病。本研究旨在回顾采用基于切除的策略治疗 IV 型肝门部胆管癌患者的经验。
回顾性分析 2006 年至 2015 年间连续诊断为 IV 型肝门部胆管癌的患者的病历。主要评估的手术结果和长期生存。
在 332 例 IV 型肿瘤患者中,216 例(65.1%)接受了切除术。左半肝三叶切除术是最常见的手术(112 例)。131 例患者行联合血管切除术。手术时间中位数为 607(范围 356-1045)min,失血量为 1357(209-10349)ml。90 例(41.7%)患者出现 Clavien-Dindo 分级 III 级或更高级别的并发症,4 例(1.9%)患者在 90 天内死于并发症。肿瘤切除的 216 例患者的生存率优于未切除肿瘤的 116 例患者(5 年时为 32.8%比 1.5%;P<0.001)。切除后 pN0M0 疾病的患者 5 年生存率为 53%。经皮肝穿刺胆道引流、输血、淋巴结转移和远处转移是生存的独立负预后因素。
尽管 IV 型肿瘤的切除技术要求高,发病率高,但在选择的患者中可以进行低死亡率手术,并提供更好的生存机会。